CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma...
Phase 2
Rochester, Minnesota, United States and 24 other locations
therapy per local standard of care (SoC), best supportive care (BSC)) on protocol survivor follow up) in patients with advanced non-ocular melanoma...
Phase 2, Phase 3
Rochester, Minnesota, United States and 70 other locations
This study observes the antitumor activity, safety, tolerability, PK, and pharmacodynamics in patients with inoperable and/or metastatic melanoma...
Phase 2
Rochester, Minnesota, United States and 43 other locations
of ANV419 with anti-PD1 antibody or with anti-CTLA4 antibody in adult participants with advanced (unresectable or metastatic) cutaneous melanoma...
Phase 1, Phase 2
Rochester, Minnesota, United States and 24 other locations
efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma...
Phase 3
Rochester, Minnesota, United States and 45 other locations
sub-type 1 receptor (MC1R) is being evaluated as a monotherapy and in combination with Nivolumab in subjects with unresectable and metastatic melanoma...
Phase 1, Phase 2
Rochester, Minnesota, United States and 9 other locations
attracting MDSCs. This first study will enroll participants with melanoma, as melanoma cancer has been shown to be able to attract ...
Phase 1
Rochester, Minnesota, United States and 5 other locations
antigen (HLA)-A\*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotin...
Phase 2, Phase 3
Rochester, Minnesota, United States and 65 other locations
The primary purpose of this study is to evaluate the efficacy of LXH254 combinations in previously treated unresectable or metastatic melanoma...
Phase 2
Rochester, Minnesota, United States and 34 other locations
not worse than nivolumab + relatlimab FDC intravenous (IV) administration in participants with previously untreated metastatic or unresectable melanoma...
Phase 3
Rochester, Minnesota, United States and 189 other locations
Clinical trials
Research sites
Resources
Legal